Synta Earns $25M Milestone From GSK For Melanoma Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnered with GSK on elesclomol, Synta anticipates “go, no go” decision in late 2008 or early 2009.
You may also be interested in...
Synta And Roche Agree To Co-Develop Anti-Inflammatory Drugs
Deal for Synta’s CRAC channel inhibitor brings $25 million upfront plus potential for $1 billion in milestones.
Synta And Roche Agree To Co-Develop Anti-Inflammatory Drugs
Deal for Synta’s CRAC channel inhibitor brings $25 million upfront plus potential for $1 billion in milestones.
GSK/Synta Elesclomol Analysis Shows Stronger Benefit In Treatment Naive Patients
Data is the basis for Phase III study design, with filing targeted for 2009.